Milritrac
Intratracheal Milrinone Enhanced CPR
Investigating whether intratracheal milrinone during cardiac arrest improves return of spontaneous circulation in a porcine model.
The Problem
Neurologically intact survival from cardiac arrest remains only 5-10%. Epinephrine is the only vasopressor currently recommended despite limited evidence for neurologic benefit. During cardiac arrest, the right ventricle dilates due to pulmonary vasoconstriction from hypoxemia, hypercapnia, and acidosis.
Our Approach
Prospective randomized blinded animal study comparing intratracheal milrinone-enhanced CPR (MeCPR) versus standard CPR in a porcine model. Milrinone's pulmonary vasodilator and inotropic effects may improve blood flow during resuscitation without the systemic hypotension seen with IV administration.
Innovation
First study of intratracheal milrinone in cardiac arrest. Unlike IV sodium nitroprusside which causes pulmonary shunting and desaturation, inhaled milrinone only affects ventilated lung areas, improving V/Q matching while reducing pulmonary vascular resistance.
Project Timeline
- Lawrence Leroux (PI)
- Louis-Philippe Fortier (Co-PI)
- Emmanuel Charbonney
- André Denault
ZOLL Foundation - $33,199 USD (2021-2023)
Département d'anesthésiologie UdeM - $20,000 CAD
22 pig randomized controlled trial completed